Utilizing genomics to identify novel immunotherapeutic targets in multiple myeloma high-risk subgroups
Abstract Background Immunotherapy is now standard of care for multiple myeloma (MM), where the most common targets are B cell maturation antigen, CD38, and G protein-coupled receptor class C group 5 member D (GPRC5D). However, additional novel targets are needed to counter tumor heterogeneity, there...
Saved in:
| Main Authors: | Enze Liu, Oumaima Jaouadi, Riya Sharma, Nathan Becker, Travis S. Johnson, Parvathi Sudha, Vivek S. Chopra, Faiza Zafar, Habib Hamidi, Charlotte Pawlyn, Attaya Suvannasankha, Rafat Abonour, Brian A. Walker |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | Genome Medicine |
| Online Access: | https://doi.org/10.1186/s13073-025-01503-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Peptide-Based Immunotherapeutics and Vaccines
by: Pedro A. Reche, et al.
Published: (2014-01-01) -
On Quasi S-Propermutable Subgroups of Finite Groups
by: Hong Yang, et al.
Published: (2020-01-01) -
Impact of myosteatosis on prognosis in multiple myeloma patients: A subgroup analysis of 182 cases and development of a nomogram
by: Jun-Peng Liu, et al.
Published: (2025-04-01) -
Current Immunotherapeutic Approaches in Pancreatic Cancer
by: Shigeo Koido, et al.
Published: (2011-01-01) -
Peptide-Based Immunotherapeutics and Vaccines 2015
by: Pedro Reche, et al.
Published: (2015-01-01)